Karolinska Development
An investment company that finances and supports innovative life science ventures.
KDEV | ST
Overview
Corporate Details
- ISIN(s):
- SE0002190850 (+1 more)
- LEI:
- 54930011ZA52NKO5W681
- Country:
- Sweden
- Address:
- Nanna Svartz väg 6A, 171 65 Solna
Description
Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-04-28 12:00 | Swedish | 6.3 MB | |||
| 2015-04-28 12:00 | English | 6.3 MB | |||
| 2015-04-28 07:30 |
Karolinska Development meddelar preliminär portföljvärdering för delårsrapport …
|
Swedish | 280.1 KB | ||
| 2015-04-28 07:30 |
Karolinska Development announces preliminary portfolio valuation for the Januar…
|
English | 278.9 KB | ||
| 2015-04-20 14:00 |
Aprea presenterar preliminära kliniska fas Ib/II-resultat inom äggstockscancer …
|
Swedish | 2.6 MB | ||
| 2015-04-20 14:00 |
Aprea presents preliminary clinical Phase Ib/II results in ovarian cancer at AA…
|
English | 2.6 MB | ||
| 2015-04-14 08:00 |
Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
|
Swedish | 455.7 KB | ||
| 2015-04-14 08:00 |
Notice of Annual General Meeting in Karolinska Development AB (publ)
|
English | 469.4 KB | ||
| 2015-03-27 08:15 |
Clanotech beviljas särläkemedelsstatus av amerikanska FDA
|
Swedish | 279.1 KB | ||
| 2015-03-27 08:15 |
Clanotech granted Orphan Drug Designation by the U.S. FDA
|
English | 277.1 KB | ||
| 2015-03-20 08:00 |
Dilaforette receives Orphan Drug Designation in the U.S. for sevuparin in Sickl…
|
English | 277.1 KB | ||
| 2015-03-20 08:00 |
Dilaforette beviljas särläkemedelsstatus i USA för sevuparin inom sicklecellane…
|
Swedish | 280.1 KB | ||
| 2015-03-03 08:00 |
Jim Van heusden appointed CEO of Karolinska Development
|
English | 286.4 KB | ||
| 2015-03-03 08:00 |
Jim Van heusden utnämnd till VD för Karolinska Development
|
Swedish | 289.3 KB | ||
| 2015-03-02 08:00 |
Karolinska Development bekräftar full betalning i företrädesemissionen av konve…
|
Swedish | 278.3 KB |
Automate Your Workflow. Get a real-time feed of all Karolinska Development filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Karolinska Development
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Karolinska Development via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-04 | Johan Dighed | Other | Buy | 35,000 | 56,350.00 SEK |
| 2023-03-27 | Johan Dighed | Other | Buy | 50,000 | 89,000.00 SEK |
| 2023-02-17 | Hans Christopher Karl Osvald Perbandt Toll | Other | Buy | 35,000 | 72,100.00 SEK |
| 2022-12-19 | Johan Dighed | Other | Buy | 50,000 | 83,500.00 SEK |
| 2022-09-30 | Johan Dighed | Other | Buy | 40,187 | 72,336.60 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,014 | 25,780.04 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 5,000 | 14,350.00 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,276 | 26,529.36 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 4,645 | 13,331.15 SEK |
| 2020-06-23 | Hans Lennart Rudolf Wigzell | Other | Buy | 39,702 | 111,562.62 SEK |
Peer Companies
